View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 24, 2022

Mirati reports positive Phase II adagrasib data in KRAS-G12C GI cancers

In the evaluable trial subjects, the objective response rate was 41% and the disease control rate was 100%.

Mirati Therapeutics has reported positive data from the Phase II KRYSTAL-1 clinical trial assessing adagrasib at 600mg twice daily dose in already treated pancreatic ductal adenocarcinoma and other gastrointestinal (GI) tumour patients with a KRAS-G12C mutation.

Adagrasib is an investigational oral small-molecule KRAS-G12C inhibitor.

The trial included patients with cancers of the appendix, biliary tract, small bowel, oesophagus and gastro-oesophageal junction. 

As of 10 September last year, the subset of 30 GI cancer patients harbouring a KRAS-G12C mutation in the adagrasib monotherapy arm received a minimum of two lines of systemic anticancer treatments previously.

They were followed up for a median of 6.3 months

According to the findings, adagrasib had a substantial clinical activity and wide-ranging disease control.

The objective response rate (ORR) and the disease control rate (DCR) were 41% and 100%, respectively in the 27 evaluable subjects.

In evaluable individuals with pancreatic cancer and other GI tumours, the response rate (RR) was reported to be 50% and 35%, respectively.

The median progression-free survival (mPFS) was 6.6 months and 7.9 months in pancreatic cancer patients and those with the other GI tumours, respectively.

Adagrasib demonstrated to be well-tolerated with a manageable safety profile in the overall subset of subjects with KRAS-G12C GI cancers analysed in this cohort. 

Furthermore, the grade 3/4 treatment-related adverse events were observed in 27% of subjects who received adagrasib without any Grade 5 TRAEs noted.

Mirati Therapeutics research and development head and founder, president Charles Baum said: “The results demonstrated positive clinical activity in patients with KRAS-G12C GI cancers treated with single agent adagrasib, particularly in those with pancreatic cancer where options are limited.

“We continue to aggressively evaluate adagrasib as a single agent and in combination with other cancer medicines in a broad development plan to help more people living with cancer.”

In November last year, Mirati and Verastem Oncology signed a non-exclusive clinical collaboration agreement to assess adagrasib plus VS-6766 in a Phase I/II trial for non-small cell lung cancer treatment.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU